JP2015517502A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517502A5
JP2015517502A5 JP2015511789A JP2015511789A JP2015517502A5 JP 2015517502 A5 JP2015517502 A5 JP 2015517502A5 JP 2015511789 A JP2015511789 A JP 2015511789A JP 2015511789 A JP2015511789 A JP 2015511789A JP 2015517502 A5 JP2015517502 A5 JP 2015517502A5
Authority
JP
Japan
Prior art keywords
composition
antibody
fragment
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015511789A
Other languages
English (en)
Japanese (ja)
Other versions
JP6218810B2 (ja
JP2015517502A (ja
Filing date
Publication date
Priority claimed from US13/842,523 external-priority patent/US10494440B2/en
Application filed filed Critical
Publication of JP2015517502A publication Critical patent/JP2015517502A/ja
Publication of JP2015517502A5 publication Critical patent/JP2015517502A5/ja
Application granted granted Critical
Publication of JP6218810B2 publication Critical patent/JP6218810B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015511789A 2012-05-11 2013-05-10 卒中後の神経形成を促進するためのセマフォリン−4d結合分子の使用 Active JP6218810B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261646119P 2012-05-11 2012-05-11
US61/646,119 2012-05-11
US13/842,523 2013-03-15
US13/842,523 US10494440B2 (en) 2012-05-11 2013-03-15 Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
PCT/US2013/040661 WO2013170221A1 (en) 2012-05-11 2013-05-10 Use of semaphorin-4d binding molecules to promote neurogenesis following stroke

Publications (3)

Publication Number Publication Date
JP2015517502A JP2015517502A (ja) 2015-06-22
JP2015517502A5 true JP2015517502A5 (https=) 2016-07-07
JP6218810B2 JP6218810B2 (ja) 2017-10-25

Family

ID=49548777

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511789A Active JP6218810B2 (ja) 2012-05-11 2013-05-10 卒中後の神経形成を促進するためのセマフォリン−4d結合分子の使用

Country Status (18)

Country Link
US (1) US10494440B2 (https=)
EP (1) EP2846831B1 (https=)
JP (1) JP6218810B2 (https=)
KR (1) KR102105436B1 (https=)
CN (2) CN110064054A (https=)
AU (1) AU2013259192B2 (https=)
BR (1) BR112014028160B1 (https=)
CA (1) CA2872928C (https=)
DK (1) DK2846831T3 (https=)
EA (1) EA030796B1 (https=)
ES (1) ES2882881T3 (https=)
IL (1) IL235603B (https=)
MX (1) MX358991B (https=)
NZ (1) NZ630864A (https=)
PT (1) PT2846831T (https=)
SG (1) SG11201407416XA (https=)
WO (1) WO2013170221A1 (https=)
ZA (1) ZA201501674B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2647823T3 (es) 2009-05-08 2017-12-26 Vaccinex, Inc. Anticuerpos anti-CD100 y métodos de uso de los mismos
BR112014008885B1 (pt) 2011-10-11 2021-02-17 Vaccinex, Inc uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
MX377858B (es) 2013-06-25 2025-03-11 Vaccinex Inc Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos.
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
IL262232B2 (en) 2016-04-22 2024-06-01 Vaccinex Inc Integral membrane protein display on poxvirus extracellular enveloped virions
KR102449406B1 (ko) 2016-08-02 2022-09-29 백시넥스 인코포레이티드 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법
CN110325213A (zh) * 2017-02-22 2019-10-11 瓦西尼斯公司 神经退行性或神经炎性疾病中胶质细胞活化的早期检测
WO2018204895A1 (en) 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody
WO2024182357A1 (en) * 2023-02-28 2024-09-06 Brandeis University Compositions and methods for the chronic treatment of epilepsy and epileptogenesis

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗vegf抗体
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1998046769A1 (en) 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
EP0892047A3 (de) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
AU776865B2 (en) 1998-11-10 2004-09-23 University Of Rochester T cells specific for target antigens and methods and vaccines based thereon
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
AU2913801A (en) 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
AU2002329540A1 (en) 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
DE60334453D1 (de) 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
CA2554735A1 (en) * 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
EP1769078A1 (en) * 2004-07-01 2007-04-04 VIRxSYS Corporation Vector packaging cell line
EP1773885B1 (en) 2004-08-05 2010-04-21 Genentech, Inc. Humanized anti-cmet antagonists
US20060147449A1 (en) 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
AU2006235271B2 (en) 2005-04-07 2011-05-19 Novartis Vaccines And Diagnostics Inc. SEMA4D in cancer diagnosis, detection and treatment
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
US7919594B2 (en) * 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
US20090181035A1 (en) 2008-01-10 2009-07-16 Genentech, Inc. Plexind1 agonists and their use
CA2755198A1 (en) * 2009-03-13 2010-09-16 Mark L. Tykocinski Ox40/trail fusion proteins
ES2647823T3 (es) 2009-05-08 2017-12-26 Vaccinex, Inc. Anticuerpos anti-CD100 y métodos de uso de los mismos
MX2011012147A (es) 2009-05-15 2012-06-19 Irx Therapeutics Inc Inmunoterapia de vacuna.
NZ604464A (en) 2010-06-14 2014-03-28 Vaccinex Inc Anti-vegf antibodies and uses thereof
KR102003571B1 (ko) 2011-05-13 2019-07-24 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 골형성 촉진제
BR112014008885B1 (pt) 2011-10-11 2021-02-17 Vaccinex, Inc uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
MX377858B (es) 2013-06-25 2025-03-11 Vaccinex Inc Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos.
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
CN110325213A (zh) * 2017-02-22 2019-10-11 瓦西尼斯公司 神经退行性或神经炎性疾病中胶质细胞活化的早期检测

Similar Documents

Publication Publication Date Title
JP2015517502A5 (https=)
JP2019527194A5 (https=)
AU2024201029A1 (en) Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
JP2010526028A5 (https=)
JP2018517401A5 (https=)
WO2014012007A4 (en) Rspo3 binding agents and uses thereof
JP2016539096A5 (https=)
JP2018506277A5 (https=)
JP2017529838A5 (https=)
JP2009545325A5 (https=)
JP2009525764A5 (https=)
RU2015143886A (ru) Антитела к тау и способы применения
JP2016505556A5 (https=)
JP2014530239A5 (https=)
JP2018500014A5 (https=)
IL275720B (en) Use of molecules that bind semphorin-d4 for the treatment of neurodegenerative disorders
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
RU2019114679A (ru) Средства, пути применения и способы лечения синуклеопатии
JP2017500018A5 (https=)
JP2015529641A5 (https=)
JP2014158469A5 (https=)
JP2015533795A5 (https=)
JP2018510617A5 (https=)
JP2010504755A5 (https=)
JP2015533853A5 (https=)